Immune Checkpoint Blockade in HIV

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2022 Feb 5

PMID 35123267

Authors

Celine Gubser

Chris Chiu

Sharon R Lewin

Thomas A Rasmussen

Affiliations

Soon will be listed here.

Abstract

Antiretroviral therapy (ART) has dramatically improved life expectancy for people with HIV (PWH) and helps to restore immune function but is not curative and must be taken lifelong. Achieving long term control of HIV in the absence of ART will likely require potent T cell function, but chronic HIV infection is associated with immune exhaustion that persists even on ART. This is driven by elevated expression of immune checkpoints that provide negative signalling to T cells. In individuals with cancer, immune checkpoint blockade augments tumour-directed T-cell responses resulting in significant clinical cures. There is therefore high interest if ICB can contribute to HIV cure or remission by reversing HIV-latency and/or drive recovery of HIV-specific T-cells. We here review recent evidence on the role of immune checkpoints in persistent HIV infection and discuss the potential for employing immune checkpoint blockade as a therapeutic approach to target HIV persistence on ART.

Citing Articles

Bryostatin-1 enhances the proliferation and functionality of exhausted CD8+ T cells by upregulating MAP Kinase 11.

Li L, Zhao M, van Meurs M, Brouwers-Haspels I, den Dekker R, Wilmsen M Front Immunol. 2025; 15:1509874.

PMID: 39877358 PMC: 11772198. DOI: 10.3389/fimmu.2024.1509874.

Healthcare provider perspectives on integrating HIV care into cancer centers in Malawi, South Africa, Uganda, and Zimbabwe.

Montano M, Jatho A, Nassolo C, Mugisha N, Bula A, Chagomerana M Transl Oncol. 2025; 53:102273.

PMID: 39826253 PMC: 11787023. DOI: 10.1016/j.tranon.2025.102273.

Proteomic signature of HIV-associated subclinical left atrial remodeling and incident heart failure.

Peterson T, Hahn V, Moaddel R, Zhu M, Haberlen S, Palella F Nat Commun. 2025; 16(1):610.

PMID: 39800750 PMC: 11725572. DOI: 10.1038/s41467-025-55911-0.

Enhancement of Human Immunodeficiency Virus-Specific CD8 T Cell Responses with TIGIT Blockade Involves Trogocytosis.

Ghasemi N, Holder K, Ings D, Grant M Pathogens. 2025; 13(12.

PMID: 39770396 PMC: 11679564. DOI: 10.3390/pathogens13121137.

Exploring potential associations between the human microbiota and reservoir of latent HIV.

Marin-Sanchez N, Paredes R, Borgognone A Retrovirology. 2024; 21(1):21.

PMID: 39614246 PMC: 11605983. DOI: 10.1186/s12977-024-00655-w.

References

Prevost J, Edgar C, Richard J, Trothen S, Jacob R, Mumby M . HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 T Cells. J Virol. 2020; 94(7). PMC: 7081912. DOI: 10.1128/JVI.01999-19. View

Huang Y, Zhu C, Kondo Y, Anderson A, Gandhi A, Russell A . CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2014; 517(7534):386-90. PMC: 4297519. DOI: 10.1038/nature13848. View

El-Far M, Ancuta P, Routy J, Zhang Y, Bakeman W, Bordi R . Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation. J Gen Virol. 2015; 96(Pt 6):1463-1477. PMC: 4635491. DOI: 10.1099/vir.0.000065. View

Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco S, Calderon-Copete S, Pais Ferreira D . Intratumoral Tcf1PD-1CD8 T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity. 2019; 50(1):195-211.e10. DOI: 10.1016/j.immuni.2018.12.021. View

Bekerman E, Hesselgesser J, Carr B, Nagel M, Hung M, Wang A . PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy. Antimicrob Agents Chemother. 2019; 63(11). PMC: 6811450. DOI: 10.1128/AAC.01163-19. View

Muthumani K, Choo A, Shedlock D, Laddy D, Sundaram S, Hirao L . Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol. 2008; 82(23):11536-44. PMC: 2583658. DOI: 10.1128/JVI.00485-08. View

Tauriainen J, Scharf L, Frederiksen J, Naji A, Ljunggren H, Sonnerborg A . Perturbed CD8 T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci Rep. 2017; 7:40354. PMC: 5233961. DOI: 10.1038/srep40354. View

Kallies A, Zehn D, Utzschneider D . Precursor exhausted T cells: key to successful immunotherapy?. Nat Rev Immunol. 2019; 20(2):128-136. DOI: 10.1038/s41577-019-0223-7. View

Scully E, Rutishauser R, Simoneau C, Delagreverie H, Euler Z, Thanh C . Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. Ann Oncol. 2018; 29(10):2141-2142. PMC: 6225895. DOI: 10.1093/annonc/mdy259. View

10.

Vassena L, Giuliani E, Matusali G, Cohen E, Doria M . The human immunodeficiency virus type 1 Vpr protein upregulates PVR via activation of the ATR-mediated DNA damage response pathway. J Gen Virol. 2013; 94(Pt 12):2664-2669. PMC: 3955189. DOI: 10.1099/vir.0.055541-0. View

11.

Chiu C, Chang J, Dantanarayana A, Solomon A, Evans V, Pascoe R . Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. J Immunol. 2021; 208(1):54-62. PMC: 8702486. DOI: 10.4049/jimmunol.2100367. View

12.

Cook M, Kim C . Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA Oncol. 2019; 5(7):1049-1054. DOI: 10.1001/jamaoncol.2018.6737. View

13.

Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R . Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018; 175(4):998-1013.e20. PMC: 6641984. DOI: 10.1016/j.cell.2018.10.038. View

14.

Elahi S, Shahbaz S, Houston S . Selective Upregulation of CTLA-4 on CD8+ T Cells Restricted by HLA-B*35Px Renders them to an Exhausted Phenotype in HIV-1 infection. PLoS Pathog. 2020; 16(8):e1008696. PMC: 7410205. DOI: 10.1371/journal.ppat.1008696. View

15.

Motamedi M, Shahbaz S, Fu L, Dunsmore G, Xu L, Harrington R . Galectin-9 Expression Defines a Subpopulation of NK Cells with Impaired Cytotoxic Effector Molecules but Enhanced IFN-γ Production, Dichotomous to TIGIT, in HIV-1 Infection. Immunohorizons. 2019; 3(11):531-546. DOI: 10.4049/immunohorizons.1900087. View

16.

Banga R, Procopio F, Noto A, Pollakis G, Cavassini M, Ohmiti K . PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat Med. 2016; 22(7):754-61. DOI: 10.1038/nm.4113. View

17.

Gubser C, Schmaler M, Rossi S, Palmer E . Monoclonal regulatory T cells provide insights into T cell suppression. Sci Rep. 2016; 6:25758. PMC: 4876466. DOI: 10.1038/srep25758. View

18.

Colston E, Grasela D, Gardiner D, Bucy R, Vakkalagadda B, Korman A . An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients. PLoS One. 2018; 13(6):e0198158. PMC: 5991705. DOI: 10.1371/journal.pone.0198158. View

19.

Gay C, Bosch R, Ritz J, Hataye J, Aga E, Tressler R . Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. J Infect Dis. 2017; 215(11):1725-1733. PMC: 5790148. DOI: 10.1093/infdis/jix191. View

20.

Miller B, Sen D, Al Abosy R, Bi K, Virkud Y, LaFleur M . Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019; 20(3):326-336. PMC: 6673650. DOI: 10.1038/s41590-019-0312-6. View